The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
Crossref DOI link: https://doi.org/10.1186/s40360-017-0190-1
Published Online: 2017-12-13
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yang, Chih-Jen
Tsai, Ming-Ju
Hung, Jen-Yu
Lee, Mei-Hsuan
Tsai, Ying-Ming
Tsai, Yu-Chen
Hsu, Jui-Feng
Liu, Ta-Chih
Huang, Ming-Shyan
Chong, Inn-Wen